Arbor Pharmaceuticals Announces the Launch of ZINOTIC ES – A New Extra Strength Product for the Treatment of Acute Otitis Externa
AOE or “swimmer’s ear” is a common childhood infection of the ear canal characterized by intense pain and inflamed, damaged skin. Children are most susceptible to AOE, and swimming is the most common predisposing factor for acquiring the infection. When treating AOE there are three main goals to address including treating the infection, relieving the pain and restoring the integrity of the lining of the ear canal. ZINOTIC is the only family of products that addresses the three AOE treatment goals. ZINOTIC ES contains the maximum dose of pramoxine and a higher level of zinc acetate to enable greater pain relief and skin protection while treating the infection without an antibiotic.
“ZINOTIC has become an important AOE treatment option since its introduction, and new ZINOTIC ES will be a welcome addition to the ZINOTIC franchise as it further addresses the three AOE treatment goals with its enhanced, extra strength formulation,” according to
ZINOTIC ES is being promoted to U.S. pediatricians by Arbor Pharmaceuticals’ sales force and via partner companies in select regions of the U.S. For more information about ZINOTIC ES, visit www.zinotic.com. The most common side effects of pramoxine (contained in ZINOTIC ES) include redness, irritation, swelling, burning, stinging, pain or dryness at the affected area.
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a
SOURCE Arbor Pharmaceuticals